• MeiraGTx highlighted four late-stage gene therapy programs, led by AAV-AQP1 in pivotal Phase 2 for radiation-induced xerostomia with potential BLA filing early 2027.
• X-linked retinitis pigmentosa program completed Phase 3, described as BLA and MAA ready, with process performance qualification reported complete.
• AAV-GAD for Parkinson’s disease positioned as Phase 3 ready, with a potential BLA filing in 2028, supported by sham-controlled trial data.
• Ophthalmology collaboration with Eli Lilly outlined, including USD 75 million upfront cash, up to USD 135 million near-term AAV-AIPL1 milestones, royalties.
• Hologen AI transaction detailed, including USD 200 million upfront cash, a JV backed by USD 230 million committed capital to fund AAV-GAD through commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.